Bladder cancer

  title={Bladder cancer},
  author={Ashish M. Kamat and Noah M. Hahn and Jason A. Efstathiou and Seth P. Lerner and Per-Uno Malmstr{\"o}m and Woonyoung Choi and Charles C. Guo and Yair Lotan and Wassim Kassouf},
  journal={The Lancet},

Figures and Tables from this paper

Regional Therapy of Bladder Tumors
A minority of patients with muscle-invasive bladder cancer are candidates for bladder preservation with trimodal therapy of TURBT and chemoradiation, and second-line therapies such as valrubicin and combination therapiessuch as gemcitabine and docetaxel.
Commentary: Bladder cancer
The authors found that bladder preservation was a safe alternative to cystectomy in transitional cell carcinoma stages T1–4aN0M0, and pointed out that the use of bladder preservation with neoadjuvant chemotherapy usually provides the best chance of cure.
Advances in risk stratification of bladder cancer to guide personalized medicine
Risk stratification traditionally uses clinicopathologic features of the disease to provide prognostic information that assists in choosing the best therapy for each individual patient but is likely to see the inclusion of molecular subtyping with specific treatment considerations based on a tumor’s mutational profile in the next generation of risk classification.
Bladder cancer: overview and management. Part 2: muscle-invasive and metastatic bladder cancer.
The roles of the multidisciplinary team is underlined in the management of bladder cancer, specifically the role of the uro-oncology cancer specialist in the provision of reassurance and support to patients.
Current Clinical Trials in Non-muscle-Invasive Bladder Cancer: Heightened Need in an Era of Chronic BCG Shortage
This review aims to highlight emerging bladder sparing therapies and trials for NMIBC, with a need for both effective first-line alternatives as and options for patients who do not respond to BCG.
Epidermal growth factor expression as a predictor of chemotherapeutic resistance in muscle-invasive bladder cancer
The findings suggest that EGFR overexpression is associated with disease recurrence following adjuvant chemotherapy for advanced BC and in vitro experiments demonstrated that inhibition of EGFR may sensitize cellular responses to cisplatin.


Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer.
Using neoadjuvant methotrexate, vinblastine, doxorubicin, and cisplatin followed by radical cystectomy increases the likelihood of eliminating residual cancer in the Cystectomy specimen and is associated with improved survival among patients with locally advanced bladder cancer.
Bladder cancer: long-term follow-up results of patients treated with radical radiation.
Radiochemotherapy after transurethral resection for high-risk T1 bladder cancer: an alternative to intravesical therapy or early cystectomy?
  • C. Weiss, C. Wolze, C. Rödel
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2006
RT/RCT after TURBT with selective bladder preservation is a reasonable alternative to intravesical treatment or early cystectomy for high-risk T1 bladder cancer.
Bladder cancer patterns of pelvic failure: Implications for adjuvant radiation therapy.
Bladder preservation strategies.